Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy

Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy

Background and objective: The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) has been called into question on the basis of clinical trial data from the tyrosine kinase inhibitor (TKI) era. Comparative analyses of CN for patients treated with immuno-...

Full description

Bibliographic Details
Main Authors: Margaret F. Meagher, Andrea Minervini, Maria C. Mir, Clara Cerrato, Giacomo Rebez, Riccardo Autorino, Lance Hampton, Riccardo Campi, Maximilian Kriegmair, Estefania Linares, Vital Hevia, Maria Musquera, Mauricio D'Anna, Eduard Roussel, Maarten Albersen, Nicola Pavan, Francesco Claps, Alessandro Antonelli, Michele Marchioni, Nail Paksoy, Selcuk Erdem, Ithaar H. Derweesh
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:European Urology Open Science
Subjects:
Immunotherapy
Metastatic renal cell carcinoma
Nephrectomy
Tyrosine kinase inhibitor
Survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168324002490

Internet

http://www.sciencedirect.com/science/article/pii/S2666168324002490

Similar Items